These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Transvaginal color Doppler sonography and CA-125 elevation in a patient with ovarian thecoma and ascites. Williams LL; Fleischer AC; Jones HW Gynecol Oncol; 1992 Jul; 46(1):115-8. PubMed ID: 1321779 [TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of benign pelvic mass with high serum levels of CA(125)]. Zhang X; Wu LY; Li XJ; Li HJ; Zhang R; Liu LY Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):178-82. PubMed ID: 15840313 [TBL] [Abstract][Full Text] [Related]
7. Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours. Ghazizadeh M; Sasaki Y; Oguro T; Aihara K; Tenjin H; Araki T Histopathology; 1990 Aug; 17(2):123-8. PubMed ID: 2227836 [TBL] [Abstract][Full Text] [Related]
8. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms. Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567 [TBL] [Abstract][Full Text] [Related]
9. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219 [TBL] [Abstract][Full Text] [Related]
10. CA-125 concentrations in malignant and nonmalignant disease. Daoud E; Bodor G Clin Chem; 1991 Nov; 37(11):1968-74. PubMed ID: 1934471 [TBL] [Abstract][Full Text] [Related]
11. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries]. Sagan DL; Chebotareva ED; Evtushenko GV Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519 [TBL] [Abstract][Full Text] [Related]
12. Significance of some tumor markers in differential diagnosis of ovarian tumor. Zakrzewska I; Borawska R; Poznański J; Maćkowiak B Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438 [TBL] [Abstract][Full Text] [Related]
13. Tumor and serum CEA content in gynecologic neoplasms. Kula J; Richter R; Gawlikowski W; Harłozińska A Neoplasma; 1984; 31(1):89-93. PubMed ID: 6322027 [TBL] [Abstract][Full Text] [Related]
14. [A case of metaplastic Brenner tumor with elevated serum CA19-9 levels]. Nishikawa A; Fukushima M; Shimano S; Yamakawa Y; Hashimoto M; Satoh M Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov; 42(11):1579-82. PubMed ID: 2273316 [No Abstract] [Full Text] [Related]
15. Prediction of benignity of solid adnexal masses. Wang S; Johnson S Arch Gynecol Obstet; 2012 Mar; 285(3):721-6. PubMed ID: 21858439 [TBL] [Abstract][Full Text] [Related]
16. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334 [TBL] [Abstract][Full Text] [Related]
17. Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors. Gadducci A; Ciancia EM; Malagnino G; De Luca F; Campani D; Ferdeghini M; Facchini V; Pingitore R; Fioretti P Eur J Gynaecol Oncol; 1992; 13(4):346-54. PubMed ID: 1516586 [TBL] [Abstract][Full Text] [Related]